AbelZeta Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
217
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$120M
- Investors
-
8
AbelZeta General Information
Description
Developer of T cell-based therapeutics designed to address unmet medical needs in oncology and immunological diseases. The company focuses on the discovery, development, and manufacturing of personalized cell therapies targeting hematologic malignancies, solid tumors, and inflammatory and immunological conditions, enabling oncologists and immunologists to access novel treatment modalities for patients with cancer and autoimmune disorders who have limited alternatives under existing standard-of-care protocols.
Contact Information
Website
www.abelzeta.com(Operating Subsidiary)
Corporate Office
- 9605 Medical Center Drive
- Suite 100
- Rockville, MD 20850
- United States
Corporate Office
- 9605 Medical Center Drive
- Suite 100
- Rockville, MD 20850
- United States
AbelZeta Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC (Series A) | 29-Sep-2021 | $120M | Completed | Clinical Trials - Phase 1 | ||
| 10. Merger/Acquisition | 19-Feb-2021 | Completed | Clinical Trials - Phase 1 | |||
| 9. Secondary Transaction - Open Market | Completed | Clinical Trials - Phase 1 | ||||
| 8. PIPE | 30-Jan-2018 | Completed | Clinical Trials - Phase 1 | |||
| 7. PIPE | 28-Dec-2017 | Completed | Clinical Trials - Phase 1 | |||
| 6. PIPE | 19-Apr-2016 | Completed | Clinical Trials - Phase 1 | |||
| 5. PIPE | 07-Apr-2015 | Completed | Clinical Trials - Phase 1 | |||
| 4. PIPE | 16-Jul-2014 | Completed | Clinical Trials - Phase 1 | |||
| 3. PIPE | 11-Apr-2014 | $6.91M | $9.9M | Completed | Clinical Trials - Phase 1 | |
| 2. PIPE | 26-Jul-2013 | $3M | $3M | Completed | Clinical Trials - Phase 1 |
AbelZeta Comparisons
Industry
Financing
Details
AbelZeta Competitors (34)
One of AbelZeta’s 34 competitors is Iovance Biotherapeutics, a Corporation company based in San Carlos, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Alaunos Therapeutics | Formerly VC-backed | Fort Lauderdale, FL | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| PersonGen BioTherapeutics | Venture Capital-Backed | Suzhou, China |
AbelZeta Patents
AbelZeta Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222428-A1 | Cll-1/cd33 dual-targeting chimeric antigen receptors | Pending | 18-Apr-2025 | ||
| WO-2026151675-A1 | Bispecific chimeric antigen receptors targeting cd20 and bcma | Pending | 07-Jan-2025 | ||
| AU-2024255572-A1 | Bispecific chimeric antigen receptors targeting bcma and cd19 | Pending | 11-Apr-2023 | ||
| EP-4695301-A2 | Bispecific chimeric antigen receptors targeting bcma and cd19 | Pending | 11-Apr-2023 | ||
| US-20260027156-A1 | Bispecific chimeric antigen receptors targeting bcma and cd19 | Pending | 11-Apr-2023 | A61K35/17 |
AbelZeta Signals
AbelZeta Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alumni Ventures | Venture Capital | Minority | ||
| EastBridge Investment Group | Corporation | Minority | ||
| Sailing Capital | PE/Buyout | Minority |
AbelZeta Investments & Acquisitions (6)
AbelZeta’s most recent deal was a Corporate Asset Purchase with University of South Florida (GVAX vaccine) for . The deal was made on 29-Jun-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| University of South Florida (GVAX vaccine) | 29-Jun-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Chinese PLA General Hospital (CAR-T cell technology) | 09-Feb-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Agreen Biotech | 30-Sep-2014 | Merger/Acquisition | Other Healthcare Services | ||
| BioMed Immunotech | 02-Aug-2014 | Merger/Acquisition | Other Commercial Products | ||
| EastBridge Investment Group | 06-Feb-2013 | Merger/Acquisition | Investment Banks |
AbelZeta Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| BioMed Immunotech |
AbelZeta FAQs
-
When was AbelZeta founded?
AbelZeta was founded in 2001.
-
Where is AbelZeta headquartered?
AbelZeta is headquartered in Rockville, MD.
-
What is the size of AbelZeta?
AbelZeta has 217 total employees.
-
What industry is AbelZeta in?
AbelZeta’s primary industry is Drug Discovery.
-
Is AbelZeta a private or public company?
AbelZeta is a Private company.
-
What is AbelZeta’s current revenue?
The current revenue for AbelZeta is .
-
How much funding has AbelZeta raised over time?
AbelZeta has raised $120M.
-
Who are AbelZeta’s investors?
Alumni Ventures, EastBridge Investment Group, and Sailing Capital have invested in AbelZeta.
-
Who are AbelZeta’s competitors?
Iovance Biotherapeutics, Alaunos Therapeutics, Sorrento Therapeutics, Ayala Pharmaceuticals, and PersonGen BioTherapeutics are some of the 34 competitors of AbelZeta.
-
When was AbelZeta acquired?
AbelZeta was acquired on 29-Sep-2021.
-
Who acquired AbelZeta?
AbelZeta was acquired by GIC Private.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process